Amygdala Neurosciences Inc. has selected ANS-858 as its lead clinical candidate for substance use disorders, that includes alcohol and cocaine use disorders. The selective, reversible, orally bioavailable, small-molecule inhibitor of aldehyde dehydrogenase 2 (ALDH2) is designed to reduce the rewarding effects associated with alcohol and other substances.